Feedback
Settings

Settings

Goto Application

1. WO2007028968 - METHOD OF TREATING MYASTHENIA GRAVIS

PermaLink
Publication Number WO/2007/028968
Publication Date 15.03.2007
International Application No. PCT/GB2006/003265
International Filing Date 05.09.2006
IPC
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 37/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
CPC
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 38/1767
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
1767from invertebrates
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61P 21/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
04for myasthenia gravis
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
Applicants
  • EVOLUTEC LIMITED [GB]/[GB] (AllExceptUS)
  • HAMER, John [GB]/[GB] (UsOnly)
  • WESTON-DAVIES, Wynne [GB]/[GB] (UsOnly)
Inventors
  • HAMER, John
  • WESTON-DAVIES, Wynne
Agents
  • GOODFELLOW, Hugh, Robin
Priority Data
0518443.709.09.2005GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD OF TREATING MYASTHENIA GRAVIS
(FR) PROCÉDÉ DE TRAITEMENT DE LA MYASTHÉNIE GRAVE
Abstract
(EN)
The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation and in particular in the treatment of myasthenia gravis.
(FR)
La présente invention concerne l’utilisation d’agents se liant à la protéine C5 du complément dans le traitement de maladies associées à une activation inopportune du complément, en particulier dans le traitement de la myasthénie grave.
Also published as
EP1931372
US20090209459
CN101340926
CA2621697
CN103505721
DK1931372
AU2006288985
JP2009508819
NZ566789
US20160166640
US20200282018
Latest bibliographic data on file with the International Bureau
# -